Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519207 | 0.87 | EPHX1 (0.70) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL11417263 | 0.86 | RAB9A (0.84) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL1425023 | 0.86 | EPHX2 (0.74) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL24381938 | 0.85 | MEN1 (0.74) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL13651414 | 0.85 | ALDH1A1 (0.72) | RECQLEPHX2RAB9AEPHX1KMT2A | |
| SCHEMBL3960592 | 0.84 | EPHX2 (0.72) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL1425366 | 0.83 | EPHX2 (0.71) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL3958860 | 0.83 | EPHX2 (0.76) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL10211627 | 0.83 | EPHX1 (0.66) | RECQLEPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL10223153 | 0.83 | EPHX2 (0.72) | RECQLEPHX2NPC1RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | RECQL 4604/4885EPHX2 2220/4885NPC1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.